Articles

In a prospective trial, the VEGFR-2 small-molecule inhibitor apatinib has shown promising efficacy and safety signals.

Although the combination of 2 antivascular agents showed preliminary efficacy, increased cardiac toxicity has resulted in premature discontinuation of the trial.

The antibody-drug conjugate mirvetuximab soravtansine combined with pembrolizumab has a manageable safety profile and encouraging signals of clinical activity.

Fatigue and neuropathy were found to be common in patients treated with olaparib, and should be identified and managed early.

A groundbreaking report presented today at ESMO conveyed data from an interim analysis of a phase 2b trial demonstrating that the combination of NPS + trastuzumab is safe and may provide clinically meaningful benefit to women with HER2 low-expressing breast cancer, with a particularly marked benefit in the subgroup with triple-negative breast cancer.

Results from the phase 3 SOLO1 trial demonstrate a substantial, unprecedented improvement in progression-free survival for olaparib versus placebo.

Results from the KEYNOTE-100 study show that expression of PD-L1 and inflamed T-cell–associated genes are associated with clinical response in advanced, recurrent ovarian cancer.

Similar to the capsule formulation, olaparib tablets have no cumulative toxicity, few late-onset adverse events, and a low rate of treatment discontinuation.

Progression-free survival associated with rucaparib is not affected by the number of prior chemotherapy regimens.

Results suggest that the combination of durvalumab and olaparib was well-tolerated and had clinical activity in heavily pretreated, BRCA-wildtype ovarian cancer patients.